MA33566B1 - Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux - Google Patents
Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreuxInfo
- Publication number
- MA33566B1 MA33566B1 MA34666A MA34666A MA33566B1 MA 33566 B1 MA33566 B1 MA 33566B1 MA 34666 A MA34666 A MA 34666A MA 34666 A MA34666 A MA 34666A MA 33566 B1 MA33566 B1 MA 33566B1
- Authority
- MA
- Morocco
- Prior art keywords
- thiohydantoids
- heteroarylmethyl
- substituted
- anticancer drugs
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
CETTE INVENTION CONCERNE DES THIOHYDANTOÏNES (HÉTÉROARYLMÉTHYL) SUBSTITUÉES DE FORMULE GÉNÉRALE (I) ET LEURS PROCÉDÉS DE PRÉPARATION, LEUR UTILISATION DANS LE TRAITEMENT ET/OU LA PROPHYLAXIE DE CERTAINES AFFECTIONS, ET LEUR UTILISATION DANS LA PRÉPARATION DE MÉDICAMENTS POUR LE TRAITEMENT ET/OU LA PROPHYLAXIE DE CERTAINES AFFECTIONS, EN PARTICULIER LE CANCER DE LA PROSTATE.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09075421 | 2009-09-11 | ||
EP10075069 | 2010-02-17 | ||
PCT/EP2010/005297 WO2011029537A1 (fr) | 2009-09-11 | 2010-08-28 | Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33566B1 true MA33566B1 (fr) | 2012-09-01 |
Family
ID=42782041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34666A MA33566B1 (fr) | 2009-09-11 | 2012-03-08 | Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux |
Country Status (27)
Country | Link |
---|---|
US (1) | US20120251551A1 (fr) |
EP (1) | EP2475653A1 (fr) |
JP (1) | JP2013504523A (fr) |
KR (1) | KR20120065396A (fr) |
CN (1) | CN102639523A (fr) |
AR (1) | AR078166A1 (fr) |
AU (1) | AU2010294588A1 (fr) |
BR (1) | BR112012005526A2 (fr) |
CA (1) | CA2773591A1 (fr) |
CL (1) | CL2012000623A1 (fr) |
CO (1) | CO6511228A2 (fr) |
CR (1) | CR20120113A (fr) |
CU (1) | CU20120042A7 (fr) |
DO (1) | DOP2012000063A (fr) |
EA (1) | EA201200473A1 (fr) |
EC (1) | ECSP12011716A (fr) |
IL (1) | IL218390A0 (fr) |
IN (1) | IN2012DN02081A (fr) |
MA (1) | MA33566B1 (fr) |
MX (1) | MX2012002977A (fr) |
NZ (1) | NZ598643A (fr) |
PE (1) | PE20121180A1 (fr) |
SG (1) | SG178919A1 (fr) |
TN (1) | TN2012000108A1 (fr) |
TW (1) | TW201111378A (fr) |
UY (1) | UY32882A (fr) |
WO (1) | WO2011029537A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2540728B1 (fr) | 2010-02-17 | 2019-04-10 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
EP2576536B1 (fr) * | 2010-06-01 | 2016-09-14 | The University of Queensland | Inhibiteurs de la prostaglandine d2 synthase hématopoïétique |
AP2014007796A0 (en) | 2011-12-22 | 2014-07-31 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
AR091156A1 (es) | 2012-05-25 | 2015-01-14 | Jansen R & D Ireland | Nucleosidos de espirooxetano de uracilo |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
PT2935303T (pt) | 2012-12-21 | 2021-04-30 | Alios Biopharma Inc | 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv |
WO2014153280A1 (fr) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase de la rate (syk) contenant du 2-pyridyl carboxamide |
CN104341351B (zh) * | 2013-07-30 | 2018-02-06 | 北京海美源医药科技有限公司 | 一种二芳基硫代乙内酰脲衍生物及其应用 |
FI3080100T3 (fi) * | 2013-12-11 | 2023-03-15 | Celgene Quanticel Res Inc | Lysiinispesifisen demetylaasi-1:n estäjät |
CN105829296A (zh) | 2013-12-18 | 2016-08-03 | 巴斯夫欧洲公司 | 带有亚胺衍生的取代基的唑类化合物 |
US9682960B2 (en) * | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
EP3140300B1 (fr) | 2014-05-07 | 2019-08-14 | Evotec International GmbH | Quinazolines substituées par une sulfoximine destinées à des compositions pharmaceutiques |
TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
CN106187905B (zh) * | 2015-05-05 | 2020-02-21 | 北京海步医药科技股份有限公司 | 丁鲁他胺的结晶形式及其制备方法 |
JP6888000B2 (ja) | 2015-10-08 | 2021-06-16 | バイエル ファーマ アクチエンゲゼルシャフト | 新規な修飾された大環状化合物 |
WO2017060322A2 (fr) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Conjugué anticorps-médicament (adc) inhibiteur de ptefb |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
PL3601253T3 (pl) | 2017-03-28 | 2022-01-17 | Bayer Aktiengesellschaft | Nowe hamujące ptefb związki makrocykliczne |
CA3057891A1 (fr) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Nouveaux composes macrocycliques inhibiteurs de ptefb |
JP2020520373A (ja) | 2017-05-18 | 2020-07-09 | ピーアイ インダストリーズ リミテッドPi Industries Ltd | 植物病原性微生物に対して有用なホルムイミドアミジン化合物 |
JP7280286B2 (ja) | 2018-02-13 | 2023-05-23 | バイエル アクチェンゲゼルシャフト | びまん性大細胞型b細胞リンパ腫を治療するための5-フルオロ-4-(4-フルオロ-2-メトキシフェニル)-n-{4-[(s-メチルスルホンイミドイル)メチル]ピリジン-2-イル}ピリジン-2-アミンの使用 |
EP3953342A4 (fr) * | 2019-04-11 | 2023-01-11 | University of Miami | Inhibiteurs améliorés du complexe d'activation transcriptionnelle notch et leurs méthodes d'utilisation |
CA3165120A1 (fr) * | 2020-01-21 | 2021-07-29 | Berkley E. GRYDER | Heterocycles d'arylhydantoine et leurs procedes d'utilisation |
WO2022206742A1 (fr) * | 2021-03-30 | 2022-10-06 | 苏州开拓药业股份有限公司 | Procédé de synthèse d'un dérivé de thiohydantoïne au moyen d'un procédé en une étape |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
FR2716110B1 (fr) | 1994-02-16 | 1996-04-05 | Roussel Uclaf | Compositions cosmétiques ou pharmaceutiques comprenant des liposomes. |
US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
CN1129581C (zh) | 1998-09-22 | 2003-12-03 | 山之内制药株式会社 | 氰基苯基衍生物 |
US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
AU2003216581A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
WO2005005399A1 (fr) | 2003-07-02 | 2005-01-20 | Merck & Co., Inc. | Antibiotiques a base d'oxazolidinone et derives |
RU2006110561A (ru) | 2003-09-30 | 2007-10-10 | Янссен Фармацевтика Н.В. (Be) | Соединения бензоимидазола |
KR101164258B1 (ko) | 2003-12-23 | 2012-07-11 | 아스텍스 테라퓨틱스 리미티드 | 단백질 키나아제 조절제로서의 피라졸 유도체 |
JP4912148B2 (ja) | 2004-08-03 | 2012-04-11 | 中外製薬株式会社 | 新規イミダゾリジン誘導体 |
EP1790640A4 (fr) * | 2004-09-09 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | Nouveau dérivé d' imidazolidine et utilisation dudit dérivé |
EP1824829B1 (fr) | 2004-12-03 | 2010-05-05 | F. Hoffmann-Roche AG | Derives 3-substitues de pyridine en tant qu'antagonistes de h3 |
EP3970721A1 (fr) | 2005-05-13 | 2022-03-23 | The Regents Of The University Of California | Composés diarylhydantoines en tant qu'antagonistes du récepteur d'androgène pour le traitement du cancer |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
US8110594B2 (en) | 2006-03-29 | 2012-02-07 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
CA2966280A1 (fr) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Composes de diaryl-hydantoine |
EP2242745A1 (fr) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
-
2010
- 2010-08-19 TW TW099127804A patent/TW201111378A/zh unknown
- 2010-08-28 SG SG2012014262A patent/SG178919A1/en unknown
- 2010-08-28 MX MX2012002977A patent/MX2012002977A/es active IP Right Grant
- 2010-08-28 BR BR112012005526A patent/BR112012005526A2/pt not_active Application Discontinuation
- 2010-08-28 NZ NZ598643A patent/NZ598643A/xx not_active IP Right Cessation
- 2010-08-28 KR KR1020127009224A patent/KR20120065396A/ko not_active Application Discontinuation
- 2010-08-28 PE PE2012000315A patent/PE20121180A1/es not_active Application Discontinuation
- 2010-08-28 WO PCT/EP2010/005297 patent/WO2011029537A1/fr active Application Filing
- 2010-08-28 CN CN2010800508678A patent/CN102639523A/zh active Pending
- 2010-08-28 EA EA201200473A patent/EA201200473A1/ru unknown
- 2010-08-28 AU AU2010294588A patent/AU2010294588A1/en not_active Abandoned
- 2010-08-28 JP JP2012528249A patent/JP2013504523A/ja not_active Withdrawn
- 2010-08-28 US US13/394,536 patent/US20120251551A1/en not_active Abandoned
- 2010-08-28 IN IN2081DEN2012 patent/IN2012DN02081A/en unknown
- 2010-08-28 CA CA2773591A patent/CA2773591A1/fr not_active Abandoned
- 2010-08-28 EP EP10747836A patent/EP2475653A1/fr not_active Withdrawn
- 2010-09-08 UY UY0001032882A patent/UY32882A/es not_active Application Discontinuation
- 2010-09-10 AR ARP100103311A patent/AR078166A1/es unknown
-
2012
- 2012-02-29 IL IL218390A patent/IL218390A0/en unknown
- 2012-03-08 TN TNP2012000108A patent/TN2012000108A1/en unknown
- 2012-03-08 MA MA34666A patent/MA33566B1/fr unknown
- 2012-03-09 CR CR20120113A patent/CR20120113A/es unknown
- 2012-03-09 CO CO12041855A patent/CO6511228A2/es not_active Application Discontinuation
- 2012-03-09 CL CL2012000623A patent/CL2012000623A1/es unknown
- 2012-03-09 EC ECSP12011716 patent/ECSP12011716A/es unknown
- 2012-03-09 DO DO2012000063A patent/DOP2012000063A/es unknown
- 2012-03-09 CU CU20120042A patent/CU20120042A7/es unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2012000063A (es) | 2012-05-15 |
CN102639523A (zh) | 2012-08-15 |
PE20121180A1 (es) | 2012-08-24 |
AU2010294588A1 (en) | 2012-04-05 |
BR112012005526A2 (pt) | 2016-04-26 |
IN2012DN02081A (fr) | 2015-08-21 |
ECSP12011716A (es) | 2012-04-30 |
CR20120113A (es) | 2012-05-02 |
US20120251551A1 (en) | 2012-10-04 |
WO2011029537A1 (fr) | 2011-03-17 |
IL218390A0 (en) | 2012-04-30 |
CL2012000623A1 (es) | 2012-09-14 |
CU20120042A7 (es) | 2012-06-21 |
KR20120065396A (ko) | 2012-06-20 |
JP2013504523A (ja) | 2013-02-07 |
UY32882A (es) | 2011-04-29 |
TN2012000108A1 (en) | 2013-09-19 |
SG178919A1 (en) | 2012-04-27 |
EA201200473A1 (ru) | 2012-10-30 |
NZ598643A (en) | 2013-10-25 |
AR078166A1 (es) | 2011-10-19 |
TW201111378A (en) | 2011-04-01 |
EP2475653A1 (fr) | 2012-07-18 |
CA2773591A1 (fr) | 2011-03-17 |
MX2012002977A (es) | 2012-04-30 |
CO6511228A2 (es) | 2012-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33566B1 (fr) | Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux | |
CA2883210C (fr) | Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1 | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
MX356205B (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
JO3419B1 (ar) | مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr | |
TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
IN2014KN02601A (fr) | ||
MX353806B (es) | Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
PH12014502772A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
MX2011010673A (es) | Formulaciones de nanoparticulas y usos de las mismas. | |
MY157124A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
WO2008086462A3 (fr) | Dérivés de quinalozine substitués par amino en tant qu'inhibiteurs de la voie b-caténine/tcf-4 et agents de traitement du cancer | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
WO2013112950A3 (fr) | Entités chimiques particulières, compositions et procédés | |
FR2921927B1 (fr) | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
WO2009151495A3 (fr) | Composés oxazoles, compositions et procédés d'utilisation | |
Xu et al. | Novel targeted therapy for advanced gastric cancer | |
FR2985256B1 (fr) | Derives piperazinyles pour le traitement de cancers | |
UA110910C2 (uk) | Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти) | |
EP2575766A4 (fr) | Nouveaux composés pharmaceutiques | |
MX2012007471A (es) | Compuestos substituidos de pirrolo-aminopirimidina. |